Behavioral disturbance in dementia

Current Psychiatry Reports

Volumn 14, Issue 4, 2012, Pages 298-309

  Desai, Abhilash K ^c   Schwartz, Lori ^b   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

Aggression; Agitation; Apathy; Behavioral; Behavioral disturbances; Delusions; Dementia; Depression; Euphoria; Geriatric disorders; Hallucinations; Insomnia; Interventions; Non pharmacological; Pharmacological; Psychological; Psychoses; Sundowning

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CIMETIDINE; CITALOPRAM; ESCITALOPRAM; ESTROGEN; HALOPERIDOL; MELATONIN; MEMANTINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PRAZOSIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

AGITATION; APATHY; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CAREGIVER BURDEN; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FALLING; GAIT DISORDER; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INJURY; INSOMNIA; INSTITUTIONAL CARE; LOW DRUG DOSE; MOOD DISORDER; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PSYCHOLOGIC ASSESSMENT; QT PROLONGATION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEDATION; SIDE EFFECT; SLEEP DISORDER; TARDIVE DYSKINESIA; URINARY TRACT INFECTION; VISUAL HALLUCINATION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; MENTAL DISORDERS;

EID: 84865650864     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0288-5     Document Type: Article

References (175)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131-68. This reference provide the latest and most comprehensive statistics on prevalence of Alzheimer's disease and behavioral disturbances.
2. Alzheimer's Disease International. World Alzheimer Report 2010. London, Alzheimer's Disease International; 2010. http://www.alz.co.uk/research/world- report. Accessed 6 April 2012.
3. Lyketsos CG, SteinbergM, Tschanz JT, et al.Mental and behavioral disturbances in dementia: findings fromthe Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-14. (Pubitemid 30249648)
4. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170-7. (Pubitemid 351308497)
5. Wetzels RB, Zuidema SU, de Jonghe JF, et al. Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatry. 2010;18:1054-65.
6. Wetzels R, Zuidema S, Jansen I, et al. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. Int Psychogeriatr. 2010;22:1040-53.
7. Bergh S, Engedal K, Roen I, Selbaek G. The course of neuropsychiatric symptoms in patients with dementia in Norwegian nursing homes. Int Psychogeriatr. 2011;23:1231-9.
8. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): Frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatrics. 2008;46:101-6. (Pubitemid 350166585)
9. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375-98.
10. Moorhouse P, Rockwood K.Vascular cognitive impairment: current concepts and clinical development. Lancet Neurol. 2008;7:246-55. (Pubitemid 351215983)
11. Robottom BJ, Weiner WJ. Dementia in Parkinson's disease. Int Rev Neurobiol. 2009;84:229-44.
12. Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793-806.
13. Rosenblatt A, Samus QM, Steele CD, et al. The Maryland assisted living study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004;52:1618-25. (Pubitemid 41709913)
14. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc. 1996;44:1078-81. (Pubitemid 26304552)
15. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-83.
16. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment. A systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115-26. (Pubitemid 351196123)
17. Sultzer DL, Levin HS, Mahler ME, et al. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. Am J Psychiatry. 1993;150:1806-12. (Pubitemid 23356572)
18. Forsell Y, Winblad B. Major depression in a population of demented and nondemented older people: Prevalence and correlates. J Am Geriatr Soc. 1998;46:27-30. (Pubitemid 28037670)
19. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-72. (Pubitemid 43970103)
20. Tucker I. Management of inappropriate sexual behaviors in dementia: a literature review. Int Psychogeriatr. 2010;22:683-92.
21. Chow TW, Binns MA, Cummings JL, et al. Apathy symptom profile and behavioral associations in frontotemporal vs. Alzheimer's disease. Arch Neurol. 2009;66:888-93.
22. Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17:1099-105. (Pubitemid 35469216)
23. Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia -frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236:43-8. (Pubitemid 41218691)
24. Steffens DC, Otey E, Alexopoulos GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry. 2006;63:130-8. (Pubitemid 43213874)
25. Rubin EH, Veiel LL, Kinscherf DA, et al. Clinically significant depressive symptoms in very mild to mild dementia of the Alzheimer's type. Int J Geriatr Psychiatry. 2001;16:694-701. (Pubitemid 32754929)
26. Baldini-Gruber A, Zimmerman S, Boustani M, et al. Characteristics associated with depression in long-term care residents with dementia. Gerontologist. 2005;45:50-5. (Pubitemid 41606922)
27. Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66-71. (Pubitemid 29034881)
28. Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer's disease. CNS Spectr. 2005;10 Suppl 18:22-5. (Pubitemid 41784924)
29. Hoe J, Hancock G, Livingston G, Orrell M. Quality of Life of people with dementia in residential care homes. Br J Psychiatry. 2006;188:460-4.
30. Selbaek G, Engedal K. Stability of the factor structure of the Neuropsychiatric Inventory in a 31-month follow-up study of a large sample of nursing-home patients with dementia. Int Psychogeriatr. 2012;24:62-73.
31. Spalletta G, Musicco M. Padovani, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:1026-35.
32. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: a conceptual review. J Am Geriatr Soc. 1986;34:711-21. (Pubitemid 16028163)
33. Leonard R, Tinneti ME, Allore HG, et al. Potentially modifiable resident characteristics that are associated with physical or verbal aggression among nursing home residents with dementia. Arch Intern Med. 2006;166:1295-300. (Pubitemid 43967582)
34. Robinson L, Hutchings D, Dickinson HO, et al. Effectiveness and acceptance of non-pharmacological interventions to reduce wandering in dementia: a systematic review. Int J Geriatr Psychiatry. 2007;22:9-22. (Pubitemid 46117334)
35. Lantz M. Wandering in dementia. Clin Geriatrics. 2007;15:21-4. (Pubitemid 350145714)
36. Khachiyants N, Trinkle D, Son SJ, Kim KY. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8:275-87.
37. Bombois S, Derambure P, Pasquire F, Monaca C. Sleep disorders in aging and dementia. J Nutr Health Aging. 2010;14:212-7.
38. Boeve BF. REM Sleep Behavior Disorder: Update review of the core features, the RBD-Neurodegenerative Disease Association. Evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15-54.
39. Ropacki S, Jeste D. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022-30. (Pubitemid 41598255)
40. Johnson D, Watts A, Chapin B, et al. Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord. 2011;25:326-32.
41. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer's Disease: review of the brain decade. Psychosomatics. 2003;44:388-401. (Pubitemid 37071926)
42. Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011;4:281-93.
43. Zarros AC, Kalopita KS, Tsakiris ST. Serotoninergic impairment and aggressive behavior in Alzheimer's disease. Acta Neurobiol Exp (Wars). 2005;65:277-86. (Pubitemid 41243000)
44. Day K, Carreon D, Stump C. The therapeutic design of environments for people with dementia: a review of the empirical research. Gerontologist. 2000;40:397-416. (Pubitemid 32011346)
45. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry. 1998;6 Suppl 1:64-8.
46. Lancot KL, Hermann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzhiemer's disease. Int J Geriatr Psychiatry. 2002;17:531-41. (Pubitemid 34678705)
47. Baldessarini RJ, March ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res. 1992;579:152-6.
48. Zubenko GS, Moossy J, Martinez J, et al. Neurropatholic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619-24.
49. Lopez OL, Smith G, Becker JT, et al. The psychotic phenomenon in probable Alzhiemer's disease: a positron emission tomography study. J Neuropsychiatry Clin Neurosci. 2001;13:50-5. (Pubitemid 32151916)
50. Marra C, Quaranta D, Profice P, et al. Central cholinergic dysfunction measured "in vivo" correlates with different behavioral disorders in Alzheimer's disease and dementia with Lewy body. Brain Stimul. 2011. doi:10.1016/j.brs.2011.08.009.
51. Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzhiemer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777-9. (Pubitemid 33121920)
52. Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR *S/*L polymorphism and aggressive behavior in Alzheimer's disease. Arch Neurol. 2001;58:1425-8. (Pubitemid 32845994)
53. Cohen-Mansfield J, Marx MS, Freedman LS, et al. The Comprehensive Process Model of Engagement. Am J Geriatr Psychiatry. 2011;19:859-70.
54. Pitfield C, Shahriyarmolki K, Livingston G. A systematic review of stress in staff caring for people with dementia living in 24-hour care settings. Int Psychogeriatr. 2011;23:4-9.
55. Orrell M, Hancock GA, Galboda KC, et al. The needs of people with dementia in care homes: the perspectives of users, staff and family caregivers. Int Psychogeriatr. 2008;20:941-51.
56. van der Roest HG, Meiland FJM, Maroccini R, et al. Subjective needs in people with dementia: a review of the literature. Int Psychogeriatr. 2007;19:559-92. (Pubitemid 46707415)
57. Luo H, Lin M, Castle N. Physical restraint use and falls in nursing homes: A comparison between residents with and without dementia. Am J Alzheimers Dis Other Demen. 2011;26:44-50.
58. Scherder EJA, Bogen T, Eggermont LHP, et al. The more physical inactivity, the more agitation in dementia. Int Psychogeriatr. 2010;22:1203-8.
59. WangWW,MoyleW. Physical restraint use on people with dementia. A review of literature. Aust J Adv Nurs. 2005;22:46-52.
60. Ballard C, Fossey J, Chithramohan R, et al. Quality of care in people with dementia in private sector and NHS facilities for people with dementia: cross sectional survey. BMJ. 2001;323:426-7. (Pubitemid 32801395)
61. Morley J. Dementia-related agitation. JAMDA. 2011;12:611-2.
62. Desai AK. Psychotropic side effects of commonly prescribed drugs in the elderly. Primary Psychiatry. 2004;11:27-34. (Pubitemid 39129527)
63. Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: A systematic review. J Am Geriatr Soc. 2002;50:1723-32. (Pubitemid 35192547)
64. Buffum MD, Hutt E, Chang VT, et al. Cognitive impairment and pain management: Review of issues and challenges. J Rehabil Res Dev. 2007;44:315-30.
65. Bourbonnais A, Ducharme F. The meanings of screams in older people living with dementia in a nursing home. Int Psychogeriatr. 2010;22:1172-84.
66. Koppel J, Goldberg TE, Gordon ML, et al. Relationships between behavioral syndromes and cognitive domains in Alzheimer's disease: the impact of mood and psychosis. Am J Geriatr Psychiatry. 2011. doi:10.1097/JGP.0b013e3182358921
67. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-51. (Pubitemid 20257519)
68. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18:917-27.
69. Hermann N, Lanctot KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21:972-6. (Pubitemid 44596392)
70. Matsumoto N, Ikeda M, Fukuhara R, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23:219-24. (Pubitemid 46496807)
71. Craig D, Mirakhur A, Hart DJ, et al. A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2005;13:460-8.
72. Stern Y, Tang MX, Albert SM, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;227:806-12. (Pubitemid 27111316)
73. Bergvall N, Brinck P, Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. Int Psychogeriatr. 2011;23:73-85.
74. Svanberg E, Spector A, Stott J. The impact of young onset dementia on the family: a literature review. Int Psychogeriatr. 2011;23:356-71.
75. Lee DR, Thomas AJ. Sleep in dementia and caregiving -assessment and treatment implications: a review. Int Psychogeriatr. 2011;23:190-201.
76. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45-52.
77. Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23:44-53.
78. Chung JCC, Lai CKY. Elopement among community-dwelling older adults with dementia. Int Psychogeriatr. 2011;23:65-72.
79. Coen RF, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbances and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:331-6. (Pubitemid 27148454)
80. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210-5. (Pubitemid 28082663)
81. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17:403-8.
82. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol Med Sci. 2003;58A:331-53. (Pubitemid 36397051)
83. Passmore MJ, Ho A, Gallagher R. Behavioral and psychological symptoms in moderate to severe Alzheimer's disease: A palliative care approach emphasizing recognition of personhood and preservation of dignity. J Alzheimer Dis. 2012;29:1-13.
84. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22:346-72. A most recent review on the management of behavioral disturbances in patients with Alzheimer's disease.
85. Lyketsos CG, CarrilloMC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer Dement. 2011;7:532-9.
86. Koopmans RTC, Zuidema SU, Leontjevas R, Gerritsen DL. Comprehensive assessment of depression and behavioral problems in long-term care. Int Psychogeriatr. 2010;23:1054-62.
87. Desai AK, Grossberg GT. Management of Alzheimer's disease. J Gerontol Med Sci. 2003;58A:331-53. (Pubitemid 36397051)
88. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14. (Pubitemid 24382728)
89. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:9-15. (Pubitemid 17091427)
90. Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry. 2011;19:403-15.
91. Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271-84. (Pubitemid 18047596)
92. American Geriatrics Society: Guide to the management of psychotic disorders and neuropsychiatric symptoms associated with dementia in older adults. http://dementia.americangeriatrics.org/GeriPsych-index.php. Accessed 8 February 2012. Latest and most comprehensive approach to management of behavioral disturbances in patients with dementia.
93. Rabins PV, Blacker D, Rovner BW, et al. APA Work Group on Alzheimer's Disease and other Dementias. American Psychiatric Association practice guidelines for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164 Suppl 12:5-56.
94. Cohen-Mansfield L, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. Gerontol A Biol Sci Med Sci. 2007;62:908-16. (Pubitemid 350139005)
95. Manepalli J, Desai A, Sharma P. Psychosocial-environmental treatments for Alzheimer's disease. Primary Psychiatry. 2009;16:39-47.
96. Edwardsson D,Winblad B, Sandman PO. Person centered care of people with severe Alzheimer's disease: Current status and ways forward. Lancet Neurol. 2008;7:362-7. (Pubitemid 351380537)
97. O'Neil ME, Freeman M, Christensen V, et al. A systematic evidence review of non-pharmacological interventions for behavioral symptoms of dementia. VA Evidence-based Synthesis Program Reports. 2011.
98. Tune LE. Nonpharmacological treatment of inappropriate sexual behaviors in dementia: the case of the Pink Panther. Am J Geriatr Psychiatry. 2008;16:612-6.
99. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer's disease: A systematic review of efficacy. Dement Geritr Cogn Disord. 2010;30:161-78.
100. Vernooij-Dassen M, Vasse E, Zuidema S, et al. Psychosocial interventions for dementia patients in long-term care. Int Psychogeriatr. 2010;22:1121-8.
101. Kverno KS, Black BS, Nolan MT, Rabin PV. Research on treating neuropsychiatric symptoms of advanced dementia with non-pharmacological strategies, 1998-2008: a systematic literature review. Int Psychogeriatr. 2009;21:825-43. Excellent review of the literature on the efficacy of non-pharmacological strategies for the treatment of behavioral disturbances in patients with advanced dementia.
102. Forbes D, Culum I, Lischka AR, et al. Light therapy for managing cognitive, sleep, functional behavioural, or psychiatric disturbances in dementia. Cochane Database Syst Rev. 2009;(4): CD003946.
103. der Lek RF Riemersma-van, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642-55. (Pubitemid 351831594)
104. Mossello E, Ridolfi A, Mello AM, et al. Animal-assisted activity and emotional status of patients with Alzheimer's disease in day care. Int Psychogeriatr. 2011;23:899-905.
105. Smith M, Kolanowski A, Buettner LL, Buckwalter KC. Beyond bingo: meaningful activities for persons with dementia in nursing homes. Ann Long Term Care. 2009;17:22-30.
106. Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20:217-25. (Pubitemid 44436834)
107. Kovach CR, Taneli Y, Dohearty P, et al. Effect of the BACE intervention on agitation of people with dementia. Gerontologist. 2004;44:797-806. (Pubitemid 39658456)
108. Graff MJL, Vernooij-Dassen MJM, Thijssen M, et al. Effects of community occupational therapy on quality of life, mood, and health status in dementia patients and their caregivers: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2007;62:1002-9. (Pubitemid 47531217)
109. Volicer L, Simard J, Pupa JH, Medrek R, Riordan ME. Effects of continuous activity programming on the behavioral symptoms of dementia. J Am Med Direct Assoc. 2006;7:426-31. (Pubitemid 44341119)
110. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary and critique. Am J Geriatr Psychiatry. 2001;9:361-82.
111. Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol Psychol Sci Soc Sci. 1997;52:159-66.
112. Chenoweth L, King MT, Jeon YH, et al. Caring for aged dementia care resident study (CADRES) of person-centered care, dementiacare mapping, and usual care in dementia: a cluster-randomized trial. Lancet Neurol. 2009;8:317-25.
113. Landau R, Werner S. Ethical aspects of using GPS for tracking people with dementia: recommendations for practice. Int Psychogeriatr. 2012;24:358-66.
114. Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of personcentered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: A randomized controlled trial. J Am Geriatr Soc. 2004;52:1795-804. (Pubitemid 41710262)
115. Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry. 2012. doi:10.1002/gps.3769
116. Lavretsky H. Neuropsychiatric symptoms in Alzheimer's disease and related dementias: Why do treatments work in clinical practice but not in the randomized trials. Am J Geriatr Psychiatry. 2008;16:523-7
117. Naarding P, van Grevenstein M, Beekman ATF. Benefit-risk analysis for the clinician: "primum non nocere" revisited -the case for antipsychotics in the treatment of behavioral disturbances in dementia. Int J Geriatr Psychiatry. 2010;25:437-40.
118. Devanand DP, Schultz SK. Consequences of antipsychotic medications for the dementia patient. Am J Psychiatry. 2011;168:767-9.
119. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's Disease. Report of a joint task force of the European Federation of Neurological Society (EFNS) and the Movement Disorder Society -European Section (MDSES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006;13:1186-202. (Pubitemid 44581465)
120. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341-8. (Pubitemid 351549385)
121. Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709-17.
122. Howard RJ, Juszczak E, Ballard CG, et al. CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357:1382-92. (Pubitemid 47535593)
123. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-8. (Pubitemid 38326109)
124. Vidal JS, et al. Evaluation of the impact of Memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31:193-200.
125. Bannerjee S, Hellier J, DeweyM, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicenter, double-blind, placebo-controlled trial. Lancet. 2011;378:403-11.
126. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577-85.
127. Brodaty H. Antidepressant treatment in Alzheimer's Disease. Lancet. 2011;378:375-6.
128. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011; (2):CD008191.
129. Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized doubleblind pilot study. Int Psychogeriatr. 2011;23:1515-9.
130. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:169-83. Excellent review of evidence for the use of antidepressants to treat behavioral disturbances in patients with dementia.
131. Hermann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2011. doi:10.1097/JGP.0b013e31823033f3
132. Wood LD, Neumiller JJ, Setter SM. Dobbins. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother. 2010;8:294-315.
133. Culo S,Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360-4.
134. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;19:1934-43. (Pubitemid 41464695)
135. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
136. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring: US Food and Drug Administration, Public Health Advisory, Center for Drug Evaluation and Research; 2005.
137. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957-70. (Pubitemid 351367549)
138. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2011;168:71-9.
139. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-41. (Pubitemid 41713745)
140. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2010;183:E411-9.
141. Vigen CLP,MackWJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's Disease: Outcomes From CATIE-AD. Am J Psychiatry. 2011;168:831-9.
142. Knol W, Marum RJV, Jansen PAF, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661-6. (Pubitemid 351473519)
143. Ballard C, Hanney ML, Theodoulou M, et al. For the DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebocontrolled trial. Lancet Neurol. 2009;8:151-7.
144. Sultzer DL, Davis SM, Tariot PN, et al. CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844-54. (Pubitemid 351948716)
145. Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166:583-90.
146. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26:937-43.
147. Leon C, Gerretsen P, Uchida H, et al. Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep. 2010;12:28-33.
148. Corbett A, Ballard C. Antipsychotics and mortality in dementia. Am J Psychiatry. 2011;169:7-9.
149. Profenno LA, Tariot PN. Pharmacologic management of agitation in Alzhiemer's disease. Dement Geriatr Cogn Disord. 2004;17:65-77. (Pubitemid 37499970)
150. Llorente M, Urrutia V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes. 2006;24:18-24. (Pubitemid 43276936)
151. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16-22.
152. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529-38.
153. Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: does an optimal dose exist? J Pharm Pract. 2012;25:142-50.
154. Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400-5. (Pubitemid 33015127)
155. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61. (Pubitemid 28037549)
156. Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbamazepine, topiramate and gabapentin. Expert Opin Drug Saf. 2007;6:133-45. (Pubitemid 46380807)
157. Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioral and psychological symptoms of dementia: a review of the evidence. Drugs Aging. 2008;25:187-96. (Pubitemid 351363751)
158. Ng B, Camacho A, Bardwell W, et al. Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr. 2009;21:207-8.
159. Kushnir SL. Lithium-antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry. 1986;143:378-9. (Pubitemid 16034105)
160. Teri L, et al. Alzheimer's Disease Cooperative Study: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271-8.
161. Lawlor BA, Radcliffe J, Molchan SA, et al. A pilot placebocontrolled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry. 1994;9:55-9. (Pubitemid 24031264)
162. Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18:1078-92.
163. Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68:833-44.
164. Neugroschl J, Wang S. Alzheimer's Disease: Diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med. 2011;78:596-612.
165. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in Alzheimer's disease patients with agitation and aggression. Am J Geriatr Psychiatry. 2009;17:744-51.
166. Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19:23-8. (Pubitemid 40488660)
167. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222-30. (Pubitemid 27198798)
168. Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized double-blind trial. Am J Geriatr Psychiatry. 1999;7:339-48. (Pubitemid 29468663)
169. Desai AK, Grossberg GT. Buspirone in Alzheimer's disease. Exp Rev Neurother. 2003;3:19-28. (Pubitemid 36077406)
170. Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebocontrolled trial of institutionalized patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2009;17:166-9.
171. Rao V, Lyketsos CG. The benefits and risks of ECTs for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15:729-35.
172. Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry. 2012;20:61-72.
173. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-98. (Pubitemid 351944940)
174. Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. Int J Geriatr Psychiatry. 2011;26:1012-8.
175. Hori K, Konishi K, Watanabe K, et al. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer's disease. Neuropsychobiology. 2011;63:147-53.